Clinical Trials Logo

Osteoporosis clinical trials

View clinical trials related to Osteoporosis.

Filter by:

NCT ID: NCT03916289 Recruiting - Osteoporosis Clinical Trials

A Tiered Management System of Osteoporosis in China

Start date: November 1, 2018
Phase:
Study type: Observational [Patient Registry]

There is a management gap in China. This study aims to establish a tiered management system of osteoporosis for Chinese patients. Including: 1. Developing a national hierarchical health management network platform for middle-aged and elderly osteoporosis patients. With this platform, the data of medical records, laboratory results would be shared between medical institutions. And primary hospitals can refer the patients to the nearest medical centre for advanced auxiliary examinations and diagnosis. 2. Establishing a muti-level hospital collaboration, doctor-patient interaction management model of osteoporosis. 3. To explore and establish a early warning and screening pathways for osteoporosis.

NCT ID: NCT03910348 Completed - Clinical trials for Osteoporosis, Postmenopausal

Effects of Whole-Body Vibration and High Impact Exercises in Postmenopausal Women

Start date: January 2010
Phase: N/A
Study type: Interventional

We investigated the effects of whole body vibration (WBV) and high-impact (HI) exercises in postmenopausal women with low bone mineral density. In summary, WBV exercises are effective in preventing bone loss and WBV and HI exercise programs are effective in decreasing fall risk, increasing health-related quality of life and improving depressive symptoms

NCT ID: NCT03901989 Completed - Osteoporosis Clinical Trials

Treatment of Osteoporosis - TOP1 Clinical Study

TOP1
Start date: January 14, 2015
Phase: N/A
Study type: Interventional

This study investigates the effect of zeolite on bone mineral metabolism. The clinical parameters include bone mineral density, bone remodelling markers, fractures and fallings, the subjective evaluation of the overall health status and intensity of the musculoskeletal pain measured by VAS.

NCT ID: NCT03898024 Not yet recruiting - Clinical trials for Osteoporosis, Osteopenia

Effects of SHR-1222 on Vascular Inflammatory Factors in Patients With Low Bone Mass

Start date: April 2019
Phase: N/A
Study type: Interventional

This study aims to investigate the effects of SHR-1222 on vascular inflammatory factors in patients with low bone mass.

NCT ID: NCT03895333 Recruiting - Hearing Loss Clinical Trials

Hearing Loss and Osteoporosis

Start date: March 1, 2019
Phase:
Study type: Observational

To compare the audiological profiles in postmenopausal women with and without osteoporosis and to examine the pattern of hearing loss in osteoporotic patients. postmenopausal women will be separated as normal, osteopenic and osteoporotic according to bone mineral densitometry results. The evaluation of hearing test will be done in these groups and the results will be compared between the groups.

NCT ID: NCT03885466 Recruiting - Osteoporosis Clinical Trials

Nordic Walking for Individuals With Osteoporosis, Vertebral Fracture or Hyperkyphosis

Start date: January 18, 2019
Phase: N/A
Study type: Interventional

Nordic walking is currently offered by a number of health care practitioners as a form of exercise therapy for older adults at risk of fracture. These include older individuals with osteoporosis, previous vertebral fracture, or hyperkyphosis. To the investigators knowledge, this practice is not evidence-based and thus potentially problematic as benefits and safety of Nordic walking for individuals with osteoporosis, fractures, or hyperkyphosis are unknown. The proposed study will answer the following principal question: Does Nordic walking improve mobility, physical function, posture, and quality of life for ambulant community dwelling individuals who have osteoporosis, a history of osteoporotic fracture, or hyperkyphosis? Participants will be randomized into either the Nordic walking intervention group, or the waiting-list control group. Participants will initially train 3 times per week for 3 months, led by peer- and/or student-instructors. The Nordic walking training will depend on the participant's skill and comfort level and will consist of walking with poles over a distance set individually for each participant. The control group will receive the same 3-month Nordic walking intervention after their control follow-up measurements are completed.

NCT ID: NCT03882853 Recruiting - Osteoporosis Clinical Trials

The Effect of Yoga Asana 'Vrksasana (Tree Pose)' on Balance in the Patients With Osteoporosis

Start date: January 8, 2019
Phase: N/A
Study type: Interventional

Patients with T score of bone mineral densitometry less than or equal to -2.5 will be included in the study. Initial evaluation consists of obtaining demographic data, performing international physical activity questionnaire (short form) Additionally; Berg balance test, timed sit and walk test, single leg stance test, tandem walk test, tandem stance test will be performed. Baseline static and dynamic balance scores of patients will be determined by the Corebalance Premiere-19 balance device. After acclimation the device and tests, 3 measurements will be made and the most successful score will be taken. The lowest value will be showing best performance. After the first evaluation, patients will be randomized using windows excel randomization option to two groups by another observer. Patients will be blinded about which exercise group they will be separated to. Both groups will be thought exercise series which will be based on recommendations which is published on October 2016 by UK national osteoporosis foundation. Patients would be encouraged to perform the exercises on recommended basis and handouts will be given to patients in both groups. The yoga group will also be taught "tree pose". Patients will be encouraged to note their exercises regularly on daily basis. Patients will be reevaluated after first and third months and balance tests will be re-performed to determine the effect of given exercises. Exclusion criteria - Neurological or vestibule dysfunctions which may affect balance - Severe mental disturbances effecting communication - Locomotor dysfunction which prevents patient to perform balance tests - Active musculoskeletal pathology which disrupt performing exercises.

NCT ID: NCT03878732 Recruiting - Clinical trials for Osteoporosis, Postmenopausal

Bindex for Osteoporosis Diagnostics

Start date: March 11, 2019
Phase:
Study type: Observational

Osteoporosis is a disease that leads to impaired skeletal strength and increased fracture risk. Among 200 million osteoporotic patients most are diagnosed only after several fractures. Furthermore, the progressively aging population will increase the prevalence of osteoporosis. It is estimated that over 75% of osteoporotic patients are not diagnosed and does not receive treatment for their condition. Bindex ultrasound device has been developed and validated in Caucasian female population. In this study, diagnostic thresholds for density index as determined with Bindex will be evaluated in two different ethnic populations.

NCT ID: NCT03870100 Not yet recruiting - Osteoporosis Clinical Trials

The PK/PD Study of A Single Subcutaneous Injection of SHR-1222 in Healthy Subjects

Start date: March 20, 2019
Phase: Phase 1
Study type: Interventional

This is a Single Center, Randomized, Double-Blind, Dose Escalation, Placebo Parallel Controlled Phaseâ… Clinical study to Evaluate the Safety, Tolerability and Pharmacokinetics, Pharmacodynamics with A Single Subcutaneous Injection of SHR-1222 in Healthy Subjects. The primary objective of this study is to investigate the safety and tolerability of a range of subcutaneous SHR-1222 in healthy subjects. Secondary objectives are to determine the pharmacokinetics (PK) and pharmacodynamics(PD) profile of SHR-1222 in healthy subjects including assessment of immunogenicity.

NCT ID: NCT03868033 Recruiting - Osteoporosis Clinical Trials

Denosumab Sequential Therapy

DST
Start date: March 7, 2019
Phase: Phase 4
Study type: Interventional

Denosumab is a potent anti-resorptive agent and is now widely used in the treatment of osteoporosis. Although denosumab has excellent effect to increase bone mass and prevent fracture in FREEDOM study with very low complications, even up to ten years, it's effect is reversible. After holding the drug, circulating denosumab levels fall rapidly, and bone resorption reaching twice baseline levels for about 6 months. How to prevent bone loss after denosumab therapy is an important issue, especially when considering the compliance, persistence, or other comorbidities of the patient. We want to verify if zoledronic acid could be used as a sequential therapy after denosumab to prevent rapid bone loss by randomized clinical trial.